Aspirin achiba ajanga ovarian cancer adoktsü aliba nungi nokdangtsü

Anogoshia aspirin low-dose ka achiba ajanga tetsürtem ovarian cancer adoktsü aliba risk shilem 23 agi tajemba kümdaktsür, ta bushisüngdang tasen ka ajanga sangdonogo.
Ovarian cancer ya gynaecological cancer rongnung tamajungtiba lir aser iba ya mapang shidak nung moputetba aser ovulation mapang inflammation ajanga cancer adoktsüba nung shilem tuluka agir ta amanger.
Aspirin achiba ajanga inflammation ajemdakja cancer adoktsü aliba nungi nokdanger ta amanger.
H. Lee-i anir US kübok Moffitt Cancer Centre and Research Institute nung bushisüngdangertemi ngutetba agi, aspirin low-dose ka achiba ajanga ovarian cancer adoktsü aliba risk tajemba kümdaktsü aser kasa mapang nung aspirin standard-dose achiba ajanga risk tali kümdaktsür.
Tetsürtem shirnoki non-aspirin anti-inflammatory drugs (NSAIDs); ibuprofen (Advil) mesera naproxen (Aleve) nunger amala hopta nung tablet 10 küm talangka chia arur, parnok dak iba tashidak adoktsü risk kanga lir.
“Onoki tangsa tangbo ovarian cancer nokdangtsü asoshi anogo shia aspirin dose tajemba ka achitsü recommend mesütettsü. Ajisüaka tetsürtemi parnok indang physician tem den ashishiteptettsü,” ta varsity, Associate Centre Director Shelley Tworoger-i ashi.
Iba bushisüngdang ya JAMA Oncology journal nung adokja liasü. Bushisüngdangertemi tetsür 200,000 dak tema indang data asadanga liasü aser parnok rongnung 1,054 dak ovarian cancer develop sür liasü.
Iba den bendenloksema bushisüngdangertemi iba sentong nung shilem agirtem aspirin (325 milligrams), low-dose aspirin (100 milligrams or less), non-aspirin NSAIDs aser acetaminophen amshiba asadanga liasü.
– Source : Internet